

GANT 61

Catalog No: tcsc1528



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

500579-04-4

Formula:

$C_{27}H_{35}N_5$

Pathway:

Autophagy;Stem Cell/Wnt

Target:

Autophagy;Gli

Purity / Grade:

>98%

Solubility:

DMSO : 17.6 mg/mL (40.97 mM; Need ultrasonic and warming)

Alternative Names:

NSC 136476

Observed Molecular Weight:

429.6


Product Description

GANT 61 is an inhibitor of **Gli1** and **Gli2** targeting the Hedgehog/GLI pathway.

IC50 & Target: Gli1/2^[1]

In Vitro: GANT61 (20 μ M) induces greater cell death than targeting Smo (cyclopamine). GANT61 (0, 5, 10, 20 μ M) inhibits clonogenic survival of human colon carcinoma cell lines. GANT61 (20 μ M, 0-72 hr) down-regulates Gli1 and Gli2 expression in HT29 cells. GANT61 (0, 10 μ M or 20 μ M) differentially regulates genes involved in the balance between cell death and cell survival^[1]. GANT-61 inhibits cell viability and induces apoptosis in pancreatic CSCs. GANT-61 inhibits expression of downstream targets of Shh pathway, decreases Gli-DNA interaction, Gli transcriptional activity and Gli nuclear translocation in pancreatic CSCs. GANT-61 differentially regulates genes involved in cell survival, cell death and pluripotency. GANT-61 inhibits motility, invasion and migration of CSCs^[2]. GANT61 sensitivity positively correlates to GLI1 and negatively to MYCN expression in the neuroblastoma cell lines tested. GANT61 downregulates GLI1, c-MYC, MYCN and Cyclin D1 expression and induces apoptosis of neuroblastoma cells^[3].

In Vivo: GANT-61 (40 mg/kg, i.p., three days per week) inhibits CSC tumor growth in NOD/SCID IL2R γ null mice^[2]. GANT61 (50 mg/kg, p.o.) enhances the effects of chemotherapeutic drugs used in the treatment of neuroblastoma in an additive or synergistic manner and reduces the growth of established neuroblastoma xenografts in nude mice^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!